MODICON 28
LOE ApproachingNDAORAL-28TABLET
Approved
May 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MODICON 28 is an oral tablet small-molecule NDA approved in 1976 by Johnson & Johnson. The specific indication and mechanism of action are not publicly detailed in available data, limiting assessment of therapeutic positioning. This legacy product represents a mature, long-established oral medication in the J&J portfolio.
LOE Approaching
Competitive pressure is moderate (30/100), but approaching loss of exclusivity signals likely downsizing of commercial infrastructure and limited career growth in brand management roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect this product's mature, stable status with minimal hiring activity. Roles remaining are primarily focused on regulatory compliance, managed decline, and customer retention rather than growth or expansion.
Regulatory Affairs SpecialistBrand Manager (Maintenance)
Worked on MODICON 28 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.